Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis



      Several studies have evaluated the efficacy of the recombinant colony-stimulating factors in reducing the severity and duration of neutropenia and the risk of infection associated with dose-intensive cancer chemotherapy. We performed a meta-analysis to define better the magnitude of this effect and to assess the generalizability of the results among different diseases and types of treatment.

      Materials and methods

      We used electronic databases and citation lists to identify controlled clinical trials of the prophylactic efficacy of the colony-stimulating factors on neutropenic complications. We selected randomized trials of the use of recombinant colony-stimulating factors before the onset of fever or neutropenia following systemic chemotherapy for solid tumors or malignant lymphomas.


      We identified eight controlled trials (n = 1144 patients) of prophylactic colony-stimulating factors, including five trials of filgrastim (recombinant granulocyte colony-stimulating factors) and three studies of lenograstim (glycosylated granulocyte recombinant colony-stimulating factors). Five trials were double-blind and placebo-controlled; three included untreated controls. Use of recombinant colony-stimulating factors was associated with a reduced risk of febrile neutropenia (odds ratio [OR] = 0.38; 95% confidence interval [CI]: 0.29 to 0.49), documented infection (OR = 0.51; 95% CI: 0.36 to 0.73), and infection-related mortality (OR = 0.60; 95% CI: 0.30 to 1.22), but a greater risk of bone pain (OR = 2.9; 95% CI: 1.6 to 4.8).


      In this meta-analysis, recombinant colony-stimulating factors were effective in reducing the risk of febrile neutropenia and documented infection associated with several malignancies and dose-intensive treatment regimens.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gabrilove J.L.
        • Jackobowski A.
        • Scher H.
        • et al.
        Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium.
        N Engl J Med. 1988; 318: 1414-1422
        • Morstyn G.
        • Campbell L.
        • Lieschke G.
        • et al.
        Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.
        J Clin Oncol. 1989; 7: 1554-1562
        • Welte K.
        • Gabrilove J.
        • Bronchud M.H.
        • et al.
        Filgrastim (r-metHuG-CSF).
        Blood. 1996; 88: 1907-1929
        • Crawford J.
        • Ozer H.
        • Stoller R.
        • et al.
        Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
        N Engl J Med. 1991; 325: 164-170
        • Trillet-Lenoir V.
        • Green J.
        • Manegold C.
        • et al.
        Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.
        Eur J Cancer. 1993; 29A: 319-324
        • Pettengell R.
        • Gurney H.
        • Radford J.A.
        • et al.
        Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma.
        Blood. 1992; 80: 1430-1436
        • Chevallier B.
        • Chollet P.
        • Merrouche Y.
        • et al.
        Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
        J Clin Oncol. 1995; 13: 1564-1571
        • Bui B.N.
        • Chevallier B.
        • Chevreau C.
        • et al.
        Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
        J Clin Oncol. 1995; 13: 2629-2636
        • Zinzani P.L.
        • Pavone E.
        • Storti S.
        • et al.
        Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma.
        Blood. 1997; 89: 3974-3979
        • Gisselbrecht C.
        • Haioun C.
        • LePage E.
        • et al.
        Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma.
        Leuk Lymphoma. 1997; 25: 289-300
        • Fossa S.D.
        • Kaye S.B.
        • Mead G.M.
        • et al.
        Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy.
        J Clin Oncol. 1998; 16: 716-724
        • Lyman G.H.
        • Lyman C.G.
        • Sanderson R.A.
        • Balducci L.
        Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.
        J Natl Cancer Inst. 1992; 85: 488-493
        • Glaspy J.A.
        • Bleecker G.
        • Crawford J.
        • et al.
        The impact of therapy with filgrastim (recombinant colony-stimulating factor) on health care costs associated with cancer chemotherapy.
        Eur J Cancer. 1993; 29: S23-S30
        • Lyman G.H.
        • Balducci L.
        A cost analysis of hematopoietic colony-stimulating factors.
        Oncology. 1995; 9: 85-91
        • Lyman G.H.
        • Kuderer N.
        • Greene J.
        • Balducci L.
        The economics of febrile neutropenia.
        Eur J Cancer. 1998; 34: 1857-1864
        • Dranitsaris H.
        Sutcliffe SB. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin’s and non-Hodgkin’s lymphoma.
        Leuk Lymphoma. 1995; 17: 139-145
        • Zagonel V.
        • Babare R.
        • Merola M.C.
        • et al.
        Cost-benefit of granulocyte-stimulating factor administration in older patients with non-Hodgkin’s lymphoma treated with combination chemotherapy.
        Ann Oncol. 1994; 5: S127-S132
        • Rubino C.
        • Laplanche A.
        • Patte C.
        • Michon J.
        Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin’s lymphoma.
        J Natl Cancer Inst. 1998; 90: 750-755
        • Lyman G.H.
        • Balducci L.
        Update of the economic analyses of the use of the colony-stimulating factors.
        Curr Opin Hematol. 1999; 6: 145-151
        • Lyman G.H.
        A novel approach to maintain planned dose chemotherapy on time.
        Eur J Cancer. 2000; 36: S15-S21
        • Ozer H.
        • Armitage J.O.
        • Bennett C.L.
        • et al.
        2000 update of recommendations for the use of hematopoietic colony-stimulating factors.
        J Clin Oncol. 2000; 18: 3558-3585
        • Moher D.
        • Jadad A.R.
        • Nichol G.
        • et al.
        Assessing the quality of ran-domized controlled trials.
        Control Clin Trials. 1995; 16: 62-73
        • Breslow N.E.
        • Day N.E.
        Statistical methods in cancer research. Volume II—the design and analysis of cohort studies.
        IARC Sci Publ. 1987; 82: 1-406
        • Peto R.
        • Pike M.C.
        • Armitage P
        • et al.
        Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples.
        Br J Cancer. 1977; 35: 1-39